About My Health Careers Internship MedBlogs Contact us

Potential Drug for Tumors in Childhood and Adult Cancers Found

by Chrisy Ngilneii on February 22, 2018 at 2:49 PM
Font : A-A+

Potential Drug for Tumors in Childhood and Adult Cancers Found

Cancer drug larotrectinib may be an effective anti-tumor drug in childhood and adult cancers, according to recent research.

The drug is designed to target a specific tumor gene mutation known as tropomyosin receptor kinases (TRK) that can occur in various tumor types.


"This drug represents a changing paradigm in cancer care where we evaluate a tumor, not only by where it exists in the body, but by the genetic mutations that are driving its growth," said Ramamoorthy Nagasubramanian, MD, an author of the study and division chief of pediatric hematology-oncology at Nemours Children's Hospital.

The study integrates findings of three phases of research, including an adult phase 1, a pediatric phase 1/2, and an adolescent/adult phase 2 study, to report on the safety and efficacy of the drug. Fifty-five patients with TRK fusion-positive cancers, detected by molecular profiling as routinely performed by each site, were enrolled across the study sites. Patients ranged in age from 4 months to 76 years old and had 17 unique cancer diagnoses, including infantile fibrosarcoma, salivary gland tumors, and thyroid cancer. Each patient received two daily doses of the drug in pill or liquid form.

Overall 75 percent of patients had their tumors respond to the treatment, with 13 percent achieving a complete response and 62 percent achieving a partial response.

Responding patients remained on treatment or underwent surgery with curative intent. The median time to response was 1.8 months (range 0.9 to 6.4). The median duration of response and progression-free survival had not been reached, but after one year, 71 percent of patients with a response were ongoing and 55 percent of all patients remained progression-free.

The treatment was well-tolerated by patients. Clinically significant adverse events were uncommon and most frequently included inflammation in the liver and other organs (alanine or aspartate aminotransferase increase), fatigue, vomiting, and dizziness.

"This study's design, simultaneously testing the efficacy and safety in adults and children, represents a strong model to follow to help advance pediatric cancer research," said Nagasubramanian. "In an era where we are not only treating tumors by names, but by their genetic signature, this research allows us to move the field forward without leaving children behind, as is so often the case in pediatric research."

The study authors note that additional data reflecting longer follow-up and a larger patient population will provide further insight into the safety profile of the drug, as well as the durability of the response.

The complete study is published in the New England Journal of Medicine.

Source: Eurekalert

News A-Z
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Drugs Banned in India Immune Checkpoint Inhibitors for Cancer Treatment Non-Communicable Diseases 

Recommended Reading
Childhood Cancer
Childhood or pediatric cancers occur in children less than 15 years of age. They are rare and ......
Brain Tumor in Children
An abnormal growth of cells in the brain is called brain tumor. Most tumors arise within the brain ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ......
Rhabdomyosarcoma is a rare type of cancer affecting the striated muscles. It mostly occurs in ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Immune Checkpoint Inhibitors for Cancer Treatment
Immune checkpoint inhibitors are promising drugs to treat a variety of cancers and the FDA has appro...
Non-Communicable Diseases
Non-Communicable Diseases (NCDs) are a group of chronic non-infectious diseases which include Cardio...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use